Last reviewed · How we verify
Relapsed acute myeloid leukemia
Approved treatments
- Neupogen · University of Chicago
- Neupogen · Amgen
Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Relapsed acute myeloid leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Relapsed acute myeloid leukemia treatment landscape brief
- Relapsed acute myeloid leukemia treatment updates RSS
Frequently asked questions about Relapsed acute myeloid leukemia
What drugs treat Relapsed acute myeloid leukemia?
Tracked treatments include Neupogen.
What is the treatment for Relapsed acute myeloid leukemia?
Standard treatment for Relapsed acute myeloid leukemia includes Neupogen. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Relapsed acute myeloid leukemia patent cliff · Relapsed acute myeloid leukemia CI report
- Treatment: Neupogen · University of Chicago
- Treatment: Neupogen · Amgen
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing